Clinical Trials Insight: 700053888

Trial Profile

Clinical Trials Insight: 700053888

Planning
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Clavulanic acid (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 06 Apr 2010 A phase II protocol for this trial has been submitted to the US Food and Drug Administration, according to a Rexahn Pharmaceuticals media release.
    • 22 Feb 2010 New trial record
    • 18 Feb 2010 The trial is expected to be initiated in the second quarter of 2010, as reported in a Rexahn Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top